Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, techno ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

Incorporating chest CT imaging and respiratory symptoms into the chronic obstructive pulmonary disease (COPD) diagnostic ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

The respiratory inhaler devices market is a critical component of the global healthcare industry, focusing on devices designed to deliver medication directly to the lungs to treat respiratory diseases ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...